Helsinn Archives | Be Korea-savvy

Home / Posts tagged Helsinn

Helsinn and Fosun Pharma Sign Exclusive License and Distribution Agreements for Aloxi®, Akynzeo® Oral, NEPA IV and Anamorelin in Mainland China, Hong Kong SAR and Macau SAR

Lugano, Switzerland – Shanghai, China, Oct. 12 (Korea Bizwire) – Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, and Fosun Pharmaceutical A.G., a corporation organised [...]

Helsinn Group Announces Oral Presentation of Data at AACR-NCI-EORTC Relating to a Potent and Highly Selective Investigational RET Inhibitor

Lugano, Switzerland, Oct. 7 (Korea Bizwire) – Helsinn Group, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, today announces the acceptance of two abstracts on a potent and [...]

Helsinn Advanced Synthesis Opens its Largest Dedicated Anticancer Bay

Biasca, Switzerland, July 30 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, announces that its manufacturing subsidiary, Helsinn Advanced Synthesis SA (HAS), which develops and manufactures Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) and anticancer compounds, has opened its largest dedicated Anticancer [...]

Helsinn Group Supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer Fund

Lugano, Switzerland, June 10 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces that Helsinn is supporting Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund, with a donation of US$100,000. The COVID Impacts Cancer campaign is an emergency initiative powered by Conquer Cancer and was created to support cancer [...]

Helsinn Announces Launch of Oral Formulation of Akynzeo® in China

Lugano, Switzerland, June 9 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce that the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting (CINV) has been launched in China. Helsinn’s partner Mundipharma (China) Pharmaceutical Company Ltd. has exclusive marketing, promotion [...]

Helsinn Announces FDA Acceptance of IND Application

Lugano, Switzerland, June 8 (Korea Bizwire) - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, today announced that on April 1, 2020 the U.S. Food and Drug Administration (FDA) completed the review of the Investigational New Drug (IND) application for TAS0953/HM06 and released a “Study May Proceed” letter for [...]

Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a Company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS Region

Lugano, Switzerland and Berlin, Germany, Jan. 27 (Korea Bizwire) - Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality cancer care products, has granted exclusive licensing rights to commercialize AKYNZEO® and ONICIT® (ALOXI®) in Russia and the CIS region for the prevention of chemotherapy-induced nausea and vomiting (CINV) to Berlin-Chemie AG (“Berlin-Chemie”), the German-based affiliate of [...]

Helsinn Demonstrates Commitment to MF CTCL with Multiple Scientific Sessions at the EORTC Cutaneous Lymphoma Meeting 2019

Lugano, Switzerland, Sept. 26 (Korea Bizwire) – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces two further abstracts have been accepted for oral presentations at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Meeting 2019. Helsinn has also announced the acceptance of an abstract for [...]

Helsinn Announces Abstract Accepted for Oral Presentation at the EORTC Cutaneous Lymphoma Meeting 2019

Lugano, Switzerland, Sept. 26 (Korea Bizwire) – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces an abstract has been accepted for oral presentation at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Meeting 2019 taking place from September 26-28, 2019 in Athens, Greece. The abstract [...]

Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology

MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, Sept. 17 (Korea Bizwire) - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, and Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, announced the opening of applications for their third annual Innovation Summit in [...]